Literature DB >> 25227910

Mesenchymal stromal cells inhibit proliferation of virus-specific CD8(+) T cells.

G Malcherek1, N Jin2, A G Hückelhoven1, J Mani1, L Wang1, U Gern1, A Diehlmann1, P Wuchter1, A Schmitt1, B Chen3, A D Ho1, M Schmitt1.   

Abstract

Mesenchymal stromal cells (MSCs) possess broad immunomodulatory capacities that are currently investigated for potential clinical application in treating autoimmune disorders. Third-party MSCs suppress alloantigen-induced proliferation of peripheral blood mononuclear cells providing the rationale for clinical use in graft-versus-host disease (GvHD). We confirmed that MSCs strongly inhibited proliferation of CD8(+) T cells in a mixed lymphocyte reaction. However, MSCs also suppressed proliferation of T cells specifically recognizing cytomegalovirus (CMV) and influenza virus. Inhibition was dose dependent, but independent of the culture medium. MSCs inhibited proliferation of specific CD8(+) T cells and the release of IFN-γ by specific CD8(+) T cells for immunodominant HLA-A2- and HLA-B7- restricted antigen epitopes derived from CMV phosphoprotein 65 and influenza matrix protein. This is in contrast to a recently reported scenario where MSCs exert differential effects on alloantigen and virus-specific T cells potentially having an impact on surveillance and prophylaxis of patients treated by MSCs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25227910     DOI: 10.1038/leu.2014.273

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  30 in total

1.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells.

Authors:  Ida Rasmusson; Olle Ringdén; Berit Sundberg; Katarina Le Blanc
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

2.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

3.  Human mesenchymal stem cells modulate B-cell functions.

Authors:  Anna Corcione; Federica Benvenuto; Elisa Ferretti; Debora Giunti; Valentina Cappiello; Francesco Cazzanti; Marco Risso; Francesca Gualandi; Giovanni Luigi Mancardi; Vito Pistoia; Antonio Uccelli
Journal:  Blood       Date:  2005-09-01       Impact factor: 22.113

Review 4.  Death and inflammation following somatic cell transplantation.

Authors:  Ian B Copland; Jacques Galipeau
Journal:  Semin Immunopathol       Date:  2011-05-01       Impact factor: 9.623

5.  Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function.

Authors:  Heba Abdelrazik; Grazia M Spaggiari; Laura Chiossone; Lorenzo Moretta
Journal:  Eur J Immunol       Date:  2011-10-18       Impact factor: 5.532

6.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

7.  Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual.

Authors:  M Sundin; C Orvell; I Rasmusson; B Sundberg; O Ringdén; K Le Blanc
Journal:  Bone Marrow Transplant       Date:  2006-06       Impact factor: 5.483

8.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

Review 9.  Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice.

Authors:  Nayoun Kim; Keon-Il Im; Jung-Yeon Lim; Eun-Joo Jeon; Young-Sun Nam; Eun-Jung Kim; Seok-Goo Cho
Journal:  Ann Hematol       Date:  2013-05-31       Impact factor: 3.673

10.  Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus.

Authors:  Nan Jin; Georg Malcherek; Jiju Mani; Romy Zurleit; Anita Schmitt; Baoan Chen; Mathias Freund; Anthony D Ho; Michael Schmitt
Journal:  Leuk Lymphoma       Date:  2013-08-31
View more
  11 in total

Review 1.  Rejuvenation of mucosal immunosenescence by adipose tissue-derived mesenchymal stem cells.

Authors:  Akitoshi Tsuruhara; Kazuyoshi Aso; Daisuke Tokuhara; Junichiro Ohori; Masaki Kawabata; Yuichi Kurono; Jerry R McGhee; Kohtaro Fujihashi
Journal:  Int Immunol       Date:  2017-01-01       Impact factor: 4.823

Review 2.  Mesenchymal Stromal Cells and Viral Infection.

Authors:  Maytawan Thanunchai; Suradej Hongeng; Arunee Thitithanyanont
Journal:  Stem Cells Int       Date:  2015-07-29       Impact factor: 5.443

3.  IL-27 regulates the adherence, proliferation, and migration of MSCs and enhances their regulatory effects on Th1 and Th2 subset generations.

Authors:  Fenghuang Xu; Junzhu Yi; Zhuoya Wang; Yejia Hu; Chunlei Han; Qun Xue; Xueguang Zhang; Xiying Luan
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

4.  Immunomodulatory effect of CD200-positive human placenta-derived stem cells in the early phase of stroke.

Authors:  TaeHo Kong; Ji-Min Park; Ji Hyon Jang; C-Yoon Kim; Sang-Hun Bae; Yuri Choi; Yun-Hwa Jeong; Chul Kim; Sung Woon Chang; Joopyung Kim; Jisook Moon
Journal:  Exp Mol Med       Date:  2018-01-12       Impact factor: 8.718

Review 5.  Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury.

Authors:  Jiang Du; Han Li; Jie Lian; Xinxing Zhu; Liang Qiao; Juntang Lin
Journal:  Stem Cell Res Ther       Date:  2020-05-24       Impact factor: 6.832

Review 6.  Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update.

Authors:  Luise Müller; Antje Tunger; Manja Wobus; Malte von Bonin; Russell Towers; Martin Bornhäuser; Francesco Dazzi; Rebekka Wehner; Marc Schmitz
Journal:  Front Cell Dev Biol       Date:  2021-02-09

7.  Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.

Authors:  Na Song; Hiroaki Wakimoto; Filippo Rossignoli; Deepak Bhere; Rachele Ciccocioppo; Kok-Siong Chen; Jasneet Kaur Khalsa; Ilenia Mastrolia; Anna Valeria Samarelli; Massimo Dominici; Khalid Shah
Journal:  Stem Cells       Date:  2021-03-07       Impact factor: 5.845

8.  Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway.

Authors:  Sonia Vallet; Muhammad Hasan Bashari; Feng-Juan Fan; Stefano Malvestiti; Andreas Schneeweiss; Patrick Wuchter; Dirk Jäger; Klaus Podar
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

Review 9.  Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.

Authors:  Maroun Khoury; Jimena Cuenca; Fernanda F Cruz; Fernando E Figueroa; Patricia R M Rocco; Daniel J Weiss
Journal:  Eur Respir J       Date:  2020-06-04       Impact factor: 16.671

Review 10.  Nanoconjugates-Based Stem Cell Therapy for the Management of COVID-19.

Authors:  Drashti Desai; Pravin Shende
Journal:  Stem Cell Rev Rep       Date:  2020-11-07       Impact factor: 6.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.